drugset
drugset / Trial / NCT05522439

A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype

NCT05522439 ↗

Phase 2 Completed 85 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients with Eosinophil Phenotype.

Timeline

Start
2022-12-22
Primary completion
2024-09-12
Completion
2024-09-12

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-1703 Monoclonal antibody — Subcutaneous

Indications

asthma